Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.35 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16610660 | 0.86 | CYP19A1 (0.36) | CYP19A1MAOAMAOBPRKCZCHRNA7 | |
| SCHEMBL16610534 | 0.86 | ALDH1A1 (0.39) | CYP19A1MAOAMAOBPRKCZMAPK1 | |
| SCHEMBL16610681 | 0.86 | ALDH1A1 (0.39) | CYP19A1MAOAMAOBPRKCZMAPK1 | |
| SCHEMBL16610525 | 0.82 | CYP19A1 (0.40) | CYP19A1MAPK1MAPT | |
| SCHEMBL16610540 | 0.78 | MAOA (0.35) | CYP19A1MAOAMAOBPRKCZ | |
| SCHEMBL16610830 | 0.75 | POLB (0.39) | CYP19A1MAOAMAOBMAPT | |
| SCHEMBL16610565 | 0.72 | DRD2 (0.40) | MAPK1 | |
| SCHEMBL16258843 | 0.71 | SLC18A3 (0.44) | CYP19A1SLC18A3MAPK1MAPTCHRNB2 | |
| SCHEMBL16754705 | 0.70 | PDE2A (0.42) | CYP19A1MAPK1MAPT | |
| Hydrochloric Acid SCHEMBL6195686 | 0.70 | CYP19A1 (0.43) | CYP19A1PRKCZSLC18A3MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143722-A1 | SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS | NIPPON SHINYAKU CO., LTD. (JP) | 2017-05-25 | — | — | US | disclosed |
| US-9580413-B2 | Substituted pyrrolidines as ROS tyrosine kinase inhibitors | NIPPON SHINYAKU CO., LTD. (JP) | 2017-02-28 | — | — | US | disclosed |
| US-20150152095-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2857398-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | Nippon Shinyaku Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152095-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | HRH4, CYP3A4, CYP3A5 | CYP19A1 761/4885MAOA 738/4885MAOB 893/4885 |
| US-20170143722-A1 | SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS | ROS1, NOX4, NOX3 | CYP19A1 2040/4885MAOA 1404/4885MAOB 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.